🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Stop by Booth #9 next week during the Antibody Engineering and Therapeutics Conference at Hilton Amsterdam, NL to learn about Harbour's fully human transgenic mouse platforms or visit harbourbiomed.com for additional information. x.com/Harbour_Ab/sta…

AbCellera & Harbour Antibodies announce technology co-offering agreement for next-generation fully-human #antibody discovery buff.ly/2ITwHhU #mAbs #biologics #antibodydiscovery #singlecell

.WuXi AppTec teams up with Harbour BioMed The #manufacturing partnership will accelerate the development of BioMed's HCAb antibody 💊 bit.ly/2K6yukk

Harbour BioMed is excited to announce Dr. Jung Lee has joined Harbour Antibodies as Vice President of Business Development. x.com/Harbour_Ab/sta…

Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers. businesswire.com/news/home/2018…

Harbour BioMed Announces Global Strategic Partnership with Kelun-Biotech to Develop and Commercialize A167, An Anti-PD-L1 Antibody, for Treatment of Cancer businesswire.com/news/home/2018…

Chinese biotech Harbour lands $85M to run cancer trials #HarbourMice fiercebiotech.com/biotech/chines…

Minmin Qin, Ph.D. (Sr. VP and Head of CMC at Harbour BioMed) will be presenting on the HCAb Mouse Technology Platform for Mono- and Bi-specific Antibodies Dec. 11th at 7:30am. Stop by Booth #315 to learn more about Harbour Biomed and Harbour Mice

Next week the Harbour Team will be attending #PEGS19. Stop by Booth #601 to learn about the Harbour Mice™ and how #HarbourMice can advance your antibodies to human clinical trials. #FullyHuman #TheOriginalHumanHCAb For additional information, email [email protected]

Harbour BioMed begins first clinical trial of next-generation fully human anti-CTLA-4 antibody for treating patients with advanced solid tumors. Trial is the first with a fully human antibody based on heavy chain only antibody technology (HCAb) businesswire.com/news/home/2019…

We are very pleased to collaborate with leading investors such as CDH Investments to accelerate the development of our clinical stage biologic assets, and to strengthen our partnering capabilities. businesswire.com/news/home/2018…

Harbour Antibodies Founder, Dr. Frank Grosveld present "In Vivo Platform for Generating Human "Heavy Chain Only" Antibodies for Drug Discovery. Booth 601 #HarbourMice #PEGS18 harbourbiomed.com/en/newsContent…